Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Atorvastatin + clopidogrel is a combination medication that pairs two distinct drugs with complementary cardiovascular benefits. This combination brings together atorvastatin, a statin that lowers cholesterol levels, with clopidogrel, an antiplatelet agent that prevents blood clots. ## Mechanism and Uses This combination is primarily prescribed for individuals at high risk of cardiovascular events such as heart attacks and strokes. Atorvastatin works by inhibiting HMG-CoA reductase, an enzyme involved in cholesterol production in the liver, which leads to lower LDL (bad cholesterol) levels and improved HDL (good cholesterol) levels[5]. Clopidogrel, on the other hand, inhibits platelet aggregation, reducing the risk of blood clot formation[5]. The combination is particularly valuable for: - Prevention of heart attacks and strokes - Post-angioplasty and stenting therapy - Management of high cholesterol alongside blood clot prevention ## Potential Interaction Concerns Interestingly, research has identified a potential interaction between these two medications. Several studies suggest that atorvastatin may reduce the effectiveness of clopidogrel[1][3][4]. This interaction appears to be dose-dependent, with higher doses of atorvastatin potentially causing greater reduction in clopidogrel's antiplatelet effects[7]. The mechanism behind this interaction involves the cytochrome P450 (CYP) enzyme system, particularly CYP3A4. Both medications are metabolized through this pathway, and atorvastatin may compete with clopidogrel for metabolism, potentially reducing clopidogrel's conversion to its active form[3][7]. A study of patients with peripheral artery disease found that those taking both medications showed significantly less platelet inhibition compared to those on clopidogrel alone[3]. However, clinical significance of this interaction remains somewhat controversial, with some larger studies showing no significant difference in clinical outcomes[4]. ## Available Formulations The combination is available under various brand names including: - Aztolet (Sun Pharmaceutical Industries) - Atorfit CV (Ajanta Pharma) - Clopitorva (Zydus Cadila) - Atormac CV (Macleods Pharmaceuticals) - Clavilip (Intas Pharmaceuticals) - Storvas CV (Sun Pharmaceutical) - Avas CV (Micro Labs) - Atorlip CV (Cipla) - Astin CV (Micro Labs) - Lipicure CV (Intas Pharmaceuticals)[2] ## Side Effects Common side effects include: - Diarrhea - Headache - Muscle pain - Abdominal pain - Joint pain - Nosebleeds - Sleep disturbance - Dyspepsia[2] Due to the potential interaction concerns, healthcare providers should carefully consider the benefits and risks when prescribing this combination, particularly at higher atorvastatin doses.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Atorvastatin + Clopidogrel.